BLCO:NYE-Bausch + Lomb Corp (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 18.14

Change

+0.28 (+1.57)%

Market Cap

USD 7.27B

Volume

0.22M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

+0.37 (+0.16%)

USD 66.03B
ALC Alcon AG

-0.65 (-0.75%)

USD 41.92B
RMD ResMed Inc

-0.70 (-0.30%)

USD 34.83B
BAX Baxter International Inc

-0.10 (-0.34%)

USD 16.24B
AVTR Avantor Inc

-0.07 (-0.33%)

USD 14.44B
ATR AptarGroup Inc

-0.70 (-0.44%)

USD 11.39B
TFX Teleflex Incorporated

-0.63 (-0.35%)

USD 8.27B
STVN Stevanato Group SpA

-0.13 (-0.60%)

USD 6.36B
WRBY Warby Parker Inc

-0.61 (-2.44%)

USD 2.84B
INFU InfuSystems Holdings Inc

-0.02 (-0.25%)

USD 0.18B

ETFs Containing BLCO

FSYD Fidelity Sustainable High.. 0.00 % 0.00 %

-0.11 (-0.23%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.33% 63% D 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.33% 58% F 45% F
Trailing 12 Months  
Capital Gain 8.04% 63% D 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.04% 63% D 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.97% 42% F 40% F
Dividend Return 1.97% 42% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.81% 95% A 70% C-
Risk Adjusted Return 14.27% 53% F 30% F
Market Capitalization 7.27B 50% F 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector